In the wake of the EMA’s recent recommendation against use the use of calcitonin nasal sprays due to an increased risk of cancer, Health Canada says that it is also evaluating the risks of calcitonin products. Novartis, its generic division Sandoz, and Apotex market calcitonin nasal sprays in Canada.
The agency, which says that it has not received any reports of cancer related to the use of calcitonin in the 30 years since the product was approved in Canada, gave no time frame for its review.
Read the Health Canada press release.
